Title
Category
Credits
Event date
Cost
Scratching the Surface of BTK Inhibition for Chronic Spontaneous Urticaria: Beyond Skin Deep
  • LivDerm
  • TME
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
$0.00
BTK inhibitors have demonstrated great promise for addressing various treatment challenges for chronic urticaria patients by improving symptom control and more effective targeting of disease pathways.
JAK is Out of the Box: Leveling Up Care for Severe Alopecia Areata Across Patient Populations
  • LivDerm
  • TME
  • 0.75 AAPA Category I CME
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC
  • 0.75 Participation
$0.00
Severe alopecia areata (AA) causes a significant disease burden impacting multiple aspects of patients’ health, quality of life, and daily functioning. New treatment options, including Janus kinase (JAK) inhibitors, are becoming available, but diagnosis and management can be challenging, especially for pediatric patients and those with skin of color.